McClellan’s “Smart Regulation”: More Early Testing And Phase IV Studies

Increased emphasis on early stage testing and Phase IV studies could result in lower drug development costs, FDA Commissioner Mark McClellan said Dec. 11

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet